Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 42.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 135,231 shares of the company's stock after purchasing an additional 40,436 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.14% of Scholar Rock worth $5,845,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Global Retirement Partners LLC increased its position in Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after purchasing an additional 766 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock worth $114,000 after purchasing an additional 620 shares during the last quarter. KBC Group NV purchased a new stake in shares of Scholar Rock during the fourth quarter worth about $131,000. NEOS Investment Management LLC acquired a new position in shares of Scholar Rock in the fourth quarter valued at approximately $209,000. Finally, Tema Etfs LLC acquired a new position in shares of Scholar Rock in the fourth quarter valued at approximately $209,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SRRK has been the topic of a number of analyst reports. Wedbush restated an "outperform" rating and set a $50.00 target price on shares of Scholar Rock in a research report on Wednesday, May 14th. Lifesci Capital raised Scholar Rock to a "strong-buy" rating in a research note on Tuesday. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $42.67.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, insider Akshay Vaishnaw sold 6,750 shares of the business's stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $29.72, for a total transaction of $200,610.00. Following the completion of the sale, the insider now owns 616,205 shares of the company's stock, valued at approximately $18,313,612.60. The trade was a 1.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Edward H. Myles sold 142,292 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $35.62, for a total value of $5,068,441.04. Following the sale, the chief financial officer now owns 111,345 shares of the company's stock, valued at $3,966,108.90. This represents a 56.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 181,798 shares of company stock worth $6,284,738 in the last quarter. 13.30% of the stock is owned by insiders.

Scholar Rock Trading Down 0.1%

Shares of SRRK stock traded down $0.02 during trading hours on Friday, hitting $34.23. 1,826,713 shares of the company were exchanged, compared to its average volume of 1,282,790. The firm has a fifty day moving average of $30.37 and a 200 day moving average of $36.15. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The firm has a market cap of $3.25 billion, a PE ratio of -14.57 and a beta of 0.37.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period in the previous year, the business earned ($0.59) EPS. Analysts expect that Scholar Rock Holding Co. will post -2.42 earnings per share for the current year.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.